LBL-034

N/A

Report date: 2026/03/19 17:22:25

Base Information

Drug NameLBL-034
Drug Alias Namea bispecific antibody targeting the G protein-coupled receptor class C group 5 member D (GPRC5D) and a cluster of differentiation 3 (CD3)LBL-034
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-GPRC5DCD3 T-cell engagers
TargetsG-protein coupled receptor family C group 5member DT cell surface glycoprotein CD3
Therapy Area/IndicationsMultiple MyelomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNanjing Leadsbiolabs Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNanjing Leadsbiolabs Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple MyelomaNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A